Twist Bioscience Corp
$ 57.41
13.95%
14 Apr - close price
- Market Cap 3,519,905,000 USD
- Current Price $ 57.41
- High / Low $ 59.00 / 50.99
- Stock P/E N/A
- Book Value 7.44
- EPS -1.27
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.17 %
- 52 Week High 59.00
- 52 Week Low 23.30
About
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.
Analyst Target Price
$50.89
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-02 | 2025-11-17 | 2025-08-04 | 2025-05-05 | 2025-02-03 | 2024-11-18 | 2024-08-02 | 2024-05-02 | 2024-02-02 | 2023-11-17 | 2023-08-04 | 2023-05-05 |
| Reported EPS | -0.5 | -0.45 | -0.47 | -0.66 | -0.53 | -0.59 | -1.47 | -0.79 | -0.75 | -0.81 | -0.78 | -1.04 |
| Estimated EPS | -0.43 | -0.5 | -0.57 | -0.56 | -0.63 | -0.7 | -0.77 | -0.82 | -0.78 | -0.92 | -1.14 | -1.12 |
| Surprise | -0.07 | 0.05 | 0.1 | -0.1 | 0.1 | 0.11 | -0.7 | 0.03 | 0.03 | 0.11 | 0.36 | 0.08 |
| Surprise Percentage | -16.2791% | 10% | 17.5439% | -17.8571% | 15.873% | 15.7143% | -90.9091% | 3.6585% | 3.8462% | 11.9565% | 31.5789% | 7.1429% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.54 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TWST
2026-04-14 19:09:55
A Form 144 filing by Twist Bioscience Corporation (NASDAQ: TWST) discloses proposed resales of common stock and recent insider sales by Adam Laponis. The filing details sales on three separate dates in February and April 2026, totaling over 11,600 shares with proceeds exceeding $577,000. Additionally, the document records recent issuances to Fidelity/employee plans, including ESPP purchases and restricted stock vestings.
2026-04-14 16:09:55
Twist Bioscience Corporation (TWST) stock has climbed by 11.95% due to positive sentiment around its synthetic biology advancements and increased price targets from Wall Street analysts. Evercore ISI raised its target to $56 with an Outperform rating, and Guggenheim increased its target to $55 with a Buy rating. Despite strong revenue growth, the company remains unprofitable, with insider Form 144 filings signaling potential sales that could add volatility.
2026-04-14 13:09:55
Barclays has reiterated its Buy rating for Twist Bioscience (TWST.US) and increased the target price to $55. This suggests a positive outlook from Barclays regarding the company's future performance.
2026-04-14 10:11:18
Adam Laponis, CFO of Twist Bioscience Corp (NASDAQ:TWST), sold 2597 shares worth $129,561 on April 9, 2026, at $49.889 per share. This sale, intended to cover tax obligations from restricted stock units, occurred while the stock was trading near its 52-week high after a 59% surge. Despite the recent earnings exceeding revenue forecasts, InvestingPro analysis suggests the stock might be overvalued.
2026-04-13 22:09:02
Twist Bioscience (TWST) has reported strong quarterly results with increased revenue guidance, leading to renewed analyst optimism despite recent stock volatility. While the company's valuation model suggests it is 41.4% overvalued with a fair value of $35.63 against its current price of $50.38, its P/S ratio indicates relative value compared to biotech peers. The article encourages investors to analyze the underlying financials and risks associated with its growth story.
2026-04-13 20:09:02
Twist Bioscience CFO Adam Laponis sold 2597 shares of common stock for $129,561 to cover tax obligations. This transaction occurred on April 9, 2026, with shares trading near their 52-week high after a significant surge. The company recently reported Q1 2026 earnings, exceeding revenue forecasts but falling short on EPS, and announced a licensing agreement and shareholder approvals.
